title: [Fas receptor and Fas-ligand expression by cells of primary melanoma, effect on lymphoid infiltration through tumor bed and long-term results of therapy].
abstract: Predictive significance of lymphoid infiltration (LI) at the boundary of tumor and intact tissue was evaluated as well as the effect of Fas-receptor (Fas) and Fas-ligand (FasL) melanoma cell expression and lymphoid infiltrate generation, on the one hand, and end results on the other. Samples of melanoma tissues from 283 patients given combined and complex treatment were examined by a single morphologist. Immunohistochemical analysis was done on paraffin-embedded bioptates from 61 patients with marked LI or without it, to assess Fas and FasL expression. Actuarial specific 5-year survival for LI(+++) was 86.7 +/- 5.6%, LI(++)--69.1 +/- 5.8%, LI(+)--45.4 +/- 5.3% +/- and LI(-)--45.9 +/- 5.9%. Most tumors were grade III-IV: more than half of them--up to 4 mm thick. Five-year survival among patients with tumors of the former group was 78.9 +/- 8.4%, 73.3 +/- 6.19%, 46.4 +/- 6.3% and 55.9 +/- 7.7%, respectively, while the latter group--90.4 +/- 5.3%, 70.9 +/- 7.1%, 65.0 +/- 6.9% and 69.7 +/- 8.0%, respectively. All samples from primary skin melanoma expressed Fas and FasL in 60.7%. No significant effect of FasL expression by tumor cells on LI generation and 5-year survival was observed.
authors.forename: D V
authors.initials: DV
authors.lastname: Kudriavtsev
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Mardynskiĭ
authors.forename: N Iu
authors.initials: NIu
authors.lastname: Dvinskikh
authors.forename: G T
authors.initials: GT
authors.lastname: Kudriavtseva
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D053222:Fas Ligand Protein / Q000378:metabolism*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000378:metabolism* / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000378:metabolism* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008875:Middle Aged; D012878:Skin Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D016019:Survival Analysis; D019014:fas Receptor / Q000378:metabolism*
chemical_list: D053222:Fas Ligand Protein; D019014:fas Receptor